Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. - Wikidata - wikimedia - TriplyDB

Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.

Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.

http://www.wikidata.org/entity/Q45299962

about

Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies Cardiovascular and hemodynamic effects of glucagon-like peptide-1.Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes The cardiovascular effects of GLP-1 receptor agonists.Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes.The effect of glucagon-like peptide 1 on cardiovascular risk.Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model.Glucagon-like peptide-1 and its cardiovascular effects.Direct cardiovascular effects of glucagon like peptide-1.Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1 Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial.Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis.Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.Incretin attenuates diabetes-induced damage in rat cardiac tissue.Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway

P2860

Q33949425-690FF59F-5323-4111-8D67-FEC6EBBAAC59 Q33993725-675AD453-EB72-4C10-AAB7-C08E45E9B5A3 Q34994502-C8A75928-CC8D-4FDF-9BA4-C3C1CF26010A Q36368998-5835F00F-170E-4641-9C4A-8D3B3E9077F3 Q36629691-E3208949-0EA9-4D72-AB41-21F30C51528B Q36701703-DE89009A-370D-47A0-9EFF-DAFAA2F86CE9 Q36935346-6DC3E62B-825E-4BD3-8F0E-F18C00DEB83E Q37395298-5B01A0A4-9633-4AE6-9BB1-B012CC542B29 Q37402790-7F4EB7BF-2DF5-4F5A-9E2E-F96B88426390 Q37501142-64596E5E-8A32-41F6-9A28-9A4F3E292095 Q37980019-326166B9-06AE-4FA6-9C22-50826333D5FF Q38012434-C70B3198-0016-44EB-9657-CFA6EB60E7E3 Q38033468-569C43C9-68A1-4996-B42A-F9BEEF21BA4B Q38132470-7B6EE288-B5BC-4725-B917-CCBAD084121C Q38177382-CD874AAE-BB32-4CCE-96FE-43C706AA0DB9 Q39430700-46FC6E2D-0F1D-4EC1-A7FF-D96B358885F0 Q39754261-03264960-8C38-4414-80B9-390095EBEC71 Q41503491-D7235DB3-2B35-47A6-8DF7-D15505DE0BBA Q42357170-E5A9D771-D627-42B0-B387-6A570652FC05 Q53836780-F047F621-C133-4116-8085-0FE7FCB4B181 Q58805576-A89A1A3B-2441-4CED-AA75-B617A6881171

P2860

Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.

http://www.wikidata.org/entity/Q45299962

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Effect of glucagon-like peptide-1

@nl

Effect of glucagon-like peptid ...... inamide-induced diabetic rats.

@en

type

label

Effect of glucagon-like peptide-1

@nl

Effect of glucagon-like peptid ...... inamide-induced diabetic rats.

@en

prefLabel

Effect of glucagon-like peptide-1

@nl

Effect of glucagon-like peptid ...... inamide-induced diabetic rats.

@en

P1433

Q45299962-D871479C-F055-4133-9528-AF253363904D

P1476

Q45299962-1C6CC291-3B1E-4DBC-93A9-B181CBE294E3

P2093

Q45299962-1EB60346-2990-463E-B848-6FC6EE3600A6

Q45299962-2DEB4A61-B352-48EC-AE2F-40CC945B61E6

Q45299962-3133B067-5E7E-4EF7-A20F-1404D7679247

Q45299962-65FF4BE9-2107-491B-A383-D38FEB4A26FF

P2860

Q45299962-0277C972-28C5-49A4-88D3-E24AAF536FFD

Q45299962-0A8F7852-C3AE-43AD-A2B4-B8409DB2FD9E

Q45299962-18223BB0-7502-4A4F-9CE6-14C9F5DBC333

Q45299962-27454243-4C41-43DA-A46B-8CDA8C220723

Q45299962-2D9F886D-A48E-4EFF-A972-8EC1D4AB117C

Q45299962-3115C0C3-BA5B-4EDA-84CE-37F83DC7D66C

Q45299962-3A400181-3A37-4C13-B9BE-2C5C5286ECB5

Q45299962-6DC2CAB3-3E68-4B7D-80D5-7B4D2A6D5C00

Q45299962-704EF701-928B-4245-94AF-1063D1995CBA

Q45299962-73D007EF-6E54-4421-A842-2B98B0FD8EE3

P304

Q45299962-73447CCC-503B-4FD9-BAE0-CCF580F26FE0

P31

Q45299962-A15372B0-6F01-4E79-9453-2A904CBCF1E3

P356

Q45299962-C623D85A-578C-46B4-87FE-64AF241E9ECE

P433

Q45299962-BC6F3214-30B3-427B-8918-3D898772118D

P478

Q45299962-123B4AC9-351F-4D72-B1E3-C1C7BBBE600A

P50

Q45299962-C5EDB4DE-98A8-4671-9467-C02B4F12B0F4

P577

Q45299962-C051C47C-466F-4081-958D-CCC8307A50A7

P5875

Q45299962-B230BB18-ADD6-42B0-88AC-0BA5D7DA428D

P698

Q45299962-D28A4ACE-BD75-453C-AD27-D340995F9EF7

P356

P1433

P1476

Effect of glucagon-like peptid ...... tinamide-induced diabetic rats

@en

P2093

Ahmet Gökhan Akkan

http://www.w3.org/2001/XMLSchema#string

Nilüfer Kutluata

http://www.w3.org/2001/XMLSchema#string

Sibel Ozyazgan

http://www.w3.org/2001/XMLSchema#string

Sule Beyhan Ozdaş

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Signal transduction of the GLP-1-receptor cloned from a human insulinoma

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

Regulation of contraction and relaxation in arterial smooth muscle.

Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus.

Enteroglucagon.

Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes

Effects of experimental diabetes on the responsiveness of rat aorta.

The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats.

Mediation of noradrenaline-induced contractions of rat aorta by the alpha 1B-adrenoceptor subtype

P304

119-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000084277

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230885906

http://www.w3.org/2001/XMLSchema#string

P698

15746570

http://www.w3.org/2001/XMLSchema#string